Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Nelson L. Michael, Leyi Lin et al.|The Lancet|2017Cited by 196
TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled StudyCiarán P. Kelly, Mark S. Turner, Robert Fogel et al.|Gastroenterology|2021Cited by 177
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Nelson L. Michael, Rajeshwer S. Sankhala et al.|Nature Medicine|2020Cited by 88
A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive AdultsJames E. Moon, Christian F. Ockenhouse, Jason A. Regules et al.|The Journal of Infectious Diseases|2020Cited by 46
War Wound Treatment Complications Due to Transfer of an IncN Plasmid Harboring <i>bla</i> <sub>OXA-181</sub> from Morganella morganii to CTX-M-27-Producing Sequence Type 131 Escherichia coliPatrick McGann, Emil Lesho, Erik Snesrud et al.|Antimicrobial Agents and Chemotherapy|2015Cited by 41